Get the Stockscreener App
0.0918
1.45%
-0.00135
After Hours:
.09
-0.00175
-1.91%
Galera Therapeutics Inc stock is traded at $0.0918, with a volume of 3,442.
It is down -1.45% in the last 24 hours and up +439.71% over the past month.
See More
Previous Close:
$0.0931
Open:
$0.0851
24h Volume:
3,442
Relative Volume:
2.03
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$149.05M
P/E Ratio:
0.0462
EPS:
1.9846
Net Cash Flow:
$-6.05M
1W Performance:
+439.71%
1M Performance:
+439.71%
6M Performance:
+439.71%
1Y Performance:
-96.95%
1-Day Range:
$0.085
$0.0918
1-Week Range:
$0.085
$0.095
52-Week Range:
$0.017
$0.095
Galera Therapeutics Inc Stock (GRTX) Company Profile
Name
Galera Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare GRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.0918 | 0 | 0 | 149.05M | -6.05M | 1.9846 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-19-21 | Downgrade | BofA Securities | Buy → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Dec-02-19 | Initiated | BTIG Research | Buy |
| Dec-02-19 | Initiated | BofA/Merrill | Buy |
| Dec-02-19 | Initiated | Citigroup | Buy |
| Dec-02-19 | Initiated | Credit Suisse | Neutral |
View All
Galera Therapeutics Inc Stock (GRTX) Latest News
Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake - TradingView
Parvinder Singh Hyare (NASDAQ: GRTX) discloses 6.6% Galera stake after preferred conversion - Stock Titan
Galera Therapeutics (GRTX) merger with Obsidian; OBX-115 posts 67% ORR in 15 patients - Stock Titan
Galera Therapeutics (GRTX) agrees to merger with Obsidian; S-4 includes prospectus - Stock Titan
Emerald Bioventures boosts Galera Therapeutics (GRTX) stake to 30.2% after conversion - Stock Titan
Emerald Bioventures boosts common stake in Galera Therapeutics (GRTX) - Stock Titan
GRTX SEC FilingsGalera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Galera Therapeutics (GRTX) to merge with Obsidian; OBX-115 posts 67% ORR at ASCO - Stock Titan
Galera Therapeutics (NASDAQ: GRTX) agrees to merge with Obsidian; S-4 filed - Stock Titan
Galera Therapeutics Eliminates Series B Preferred, Simplifies Equity - TipRanks
Galera converts remaining Series B preferred into 42.84M common shares - TradingView
Galera Therapeutics (OTCQB: GRTX) ends Series B preferred via full conversion - Stock Titan
Why Is Galera Therapeutics, Inc. (GRTX) Stock Up Today? - Meyka
Galera Therapeutics Expands Share Authorization, Enhances Stockholder Rights - The Globe and Mail
Galera Therapeutics Files 8-K Announcing Amendments to Certificate of Incorporation and Bylaws - Minichart
Galera Therapeutics doubles authorized shares and amends bylaws after stockholder vote - Investing.com UK
Galera Therapeutics doubles authorized shares and amends bylaws after stockholder vote By Investing.com - Investing.com South Africa
Galera Therapeutics (OTCQB: GRTX) doubles share authorization and adds written consent right - Stock Titan
Galera Therapeutics, Inc. 10-Q Quarterly Report: Financial Statements, Management Analysis, and Forward-Looking Statements for 2026 - Minichart
Galera Therapeutics, Inc. 1Q 2026: Net loss $1.61M, EPS $(0.01) — 10-Q Summary - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Galera Therapeutics (NASDAQ: GRTX) bets on Obsidian merger and $350M PIPE - Stock Titan
Galera Shareholders Approve Governance Changes and Share Increase - The Globe and Mail
Galera Therapeutics (OTCQB: GRTX) holders approve share boost and reverse split - Stock Titan
Halper Sadeh LLC is Investigating Whether XOMA, RMAX, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Emerald Bioventures details major Galera Therapeutics (GRTX) equity stake - Stock Titan
Malvern-based Galera Therapeutics to be acquired in reverse merger - MSN
Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan
Galera, Obsidian Agree to Merge, Raise $350 Million in Financing - MyChesCo
Obsidian CEO Madan Jagasia Leads Merger with Galera Therapeutics Backed by $350M Financing - INDIA New England News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-LEG, AVNS, GRTX, and GSAT - The Malaysian Reserve
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Merger Deal: Galera Therapeutics (GRTX) to Merge with Obsidian; ASCO Phase 2 Data Ahead - Stock Titan
Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan
Galera, Obsidian to Merge, Raise $350 Million in Financing - MyChesCo
Are FORA, GRTX, WBS, TALK Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
[DEF 14A] Galera Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
United StatesGoodwin Advises Obsidian Therapeutics On Merger With Galera Therapeutics And $350 Million Private Placement Financing - Mondaq
Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials - MedCity News
Mintz Advising on $350 Million Private Placement Concurrent with Obsidian Therapeutics’ and Galera Therapeutics’ Merger Transaction - Mintz
Galera Therapeutics to merge with Obsidian in $350M deal By Investing.com - Investing.com Australia
Obsidian and Galera reveal reverse merger plan - The Pharma Letter
Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement - Pharmaceutical Executive
Galera (GRTX) to Merge with Obsidian; $350M Financing Backs OBX‑115 - Stock Titan
M&A Class Action Firm Investigating Galera Acquisition - National Today
Galera and Obsidian Announce $350M Merger, Advancing Novel TIL Therapies - National Today
Merger: Galera to combine with Obsidian (NASDAQ: GRTX) with $350M PIPE commitment - Stock Titan
Obsidian Therapeutics (NASDAQ: OBX) to list after merger with Galera, $350M PIPE - Stock Titan
Galera Therapeutics (GRTX) to file Form S-4 for proposed Obsidian merger - Stock Titan
Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus
Galera Therapeutics Inc Stock (GRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Cap:
|
Volume (24h):